​

Zura Bio Stock (NASDAQ:ZURA)

ForecastRevenueOwnershipFinancialsChart
Zura Bio by TradingView

Previous Close

$3.76

52W Range

$0.97 - $4.68

50D Avg

$3.82

200D Avg

$2.04

Market Cap

$241.88M

Avg Vol (3M)

$1.66M

Beta

0.24

Div Yield

-

ZURA Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

30

IPO Date

Mar 21, 2023

Website

ZURA Performance

ZURA Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-55.19M$-62.64M$-2.68M
Net Income$-45.39M$-60.36M$3.55M
EBITDA$-55.19M$-60.56M$-27.33M
Basic EPS$-0.60$-2.09$0.21
Diluted EPS$-0.60$-2.09$0.21

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
AARDAardvark Therapeutics, Inc. Common Stock
FHTXFoghorn Therapeutics Inc.
ARCTArcturus Therapeutics Holdings Inc.
PYXSPyxis Oncology, Inc.
ENTAEnanta Pharmaceuticals, Inc.
TNYATenaya Therapeutics, Inc.
ASMBAssembly Biosciences, Inc.
SGMTSagimet Biosciences Inc.
NAUTNautilus Biotechnology, Inc.
IMRXImmuneering Corporation